Potent antitumour of the mTORC1/2 dual inhibitor AZD2014 in docetaxel‐sensitive and docetaxel‐resistant castration‐resistant prostate cancer cells

Recent studies indicate mammalian target of rapamycin (mTOR) may play an important role in PCa progression and drug resistance. Here, we investigated the effects of a novel mTORC1/C2 dual inhibitor, AZD2014, on naive and docetaxel (Doc)‐pre‐treated castration‐resistant PCa (CRPC) cells and explored...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Senmao, Sheng, Jindong, Liu, Zhenhua, Fan, Yu, Zhang, Cuijian, Lv, Tianjing, Hu, Shuai, Jin, Jie, Yu, Wei, Song, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933970/
https://www.ncbi.nlm.nih.gov/pubmed/33507584
http://dx.doi.org/10.1111/jcmm.16155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933970/
https://www.ncbi.nlm.nih.gov/pubmed/33507584
http://dx.doi.org/10.1111/jcmm.16155

Ejemplares similares